
AstraZeneca, Daiichi Sankyo's Enhertu rings up success in another breast cancer trial
Less than three weeks after AstraZeneca and Daiichi Sankyo reported positive results for oncology powerhouse Enhertu in a first-line breast cancer trial, the companies have scored again in another phase 3 breast cancer study. The Destiny-Breast11 trial has …